Source comparison
Melanotan-2 Stacking Guide: Compound Compatibility, Timing, and Mechanism Comparison
The table below maps peptide and compound compatibility with Melanotan-2 based on receptor pathway overlap, pharmacokinetic timing requirements, and expected synergistic or antagonistic interactions. This is the decision framework for any melanotan-2 stacking
This comparison does not assign a generated winner or score.
- The table below maps peptide and compound compatibility with Melanotan-2 based on receptor pathway overlap, pharmacokinetic timing requirements, and expected synergistic or antagonistic interactions. This is the decision framework for any melanotan-2 stacking guide.
- Melanotan 1
- Selective MC1R agonist
- None (MT1 selective for MC1R; MT2 acts on MC1R, MC3R, MC4R, MC5R)
- Alternating days or MT2 loading + MT1 maintenance
- Additive melanogenesis, reduced systemic sides
- Best stack for pigmentation with minimized nausea and appetite effects
- CJC-1295/Ipamorelin
- GH secretagogue (non-ghrelin pathway)
- None
- MT2 morning, CJC/Ipa evening pre-sleep
- Synergistic lipolysis and lean mass preservation
- Ideal for body recomposition without appetite disruption
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist, GH secretagogue
- Opposes MT2 MC4R appetite suppression
- Avoid combination or separate by 8+ hours
- Antagonistic appetite signaling, unpredictable nausea
- Poor compatibility due to opposing hunger signals
- AOD9604
- HGH fragment, beta-3 adrenergic lipolysis
- Can co-administer or separate by 4–6 hours
- Synergistic fat oxidation, complementary thermogenesis
- Strong compatibility for fat loss research
- 5-Amino-1MQ
- NNMT inhibitor, increases NAD+, AMPK activation
- Co-administer (oral 5-Amino-1MQ + subcutaneous MT2)
- Synergistic metabolic efficiency and insulin sensitivity
- Excellent for metabolic and recomposition research
- GHRP-2 / GHRP-6
- Avoid or use only in controlled feeding studies
- Antagonistic appetite effects, amplified nausea risk
- Not recommended for typical MT2 stacks
- PT-141 (Bremelanotide)
- Selective MC4R agonist
- High overlap (both target MC4R)
- Avoid combination
- Redundant receptor activation, amplified side effects
- No added benefit; increases adverse event risk
- BPC-157
- Tissue repair, angiogenesis, gastric protection
- Co-administer (BPC oral or subQ)
- May reduce MT2-induced nausea through gastric protection
- Good adjunct for GI side effect mitigation